Panel wants FDA to approve Xarelto as preventive stroke therapy

An FDA advisory panel endorsed the approval of anticoagulant Xarelto to prevent stroke in patients with atrial fibrillation. Panel members said they wanted more alternatives to warfarin. Xarelto developers Johnson & Johnson and Bayer expect an FDA decision in November.

View Full Article in:

New York Times (tiered subscription model), The · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT